A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study
of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics
and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing
advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.